Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.

CellTrans’s Lantidra is now the first FDA-approved cell therapy for type 1 diabetes. The therapy is made from islet cells sourced from deceased donors.

Eli Lilly is expanding its diabetes prospects by acquiring cell therapy developer Sigilon Therapeutics. The two companies are already partners in the development of a type 1 diabetes cell therapy currently in preclinical development.

Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes. The news comes two years after Medtronic submitted the system for FDA approval and three years after the company began selling the product in Europe.

Vertex Pharmaceuticals aims to use CRISPR Therapeutics’ gene-editing technology to develop type 1 diabetes cell therapies that don’t prompt the immune system to reject them. This approach could compete with a Sana Biotechnology program expected to reach its first test in humans this year.

StartUp Health’s presence at ViVE will highlight the launch of its Health Transformer University and the addition of Helmsley Charitable Trust as an investor. Its pavilion will showcase 16 health tech companies and include panel discussions on remote patient monitoring, automation and more.

Type 1 diabetes patients now have a new therapeutic option for the autoimmune disorder. Provention Bio drug Tzeild has received FDA approval for delaying the onset of the most severe stage of this chronic disease.

Vertex Pharmaceuticals already has a cell therapy candidate for type 1 diabetes but the company says acquiring rival ViaCyte will provide it with complementary assets and technologies. The two companies already share a partner in common: both have therapeutic candidates that use the gene-editing capabilities of CRISPR Therapeutics.

Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered via engineered viruses. The startup plans to use its new capital to develop lead programs in Duchenne muscular dystrophy and type 1 diabetes.

The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.

Provention Bio needs to show the FDA that the drug substance produced from its contract manufacturer is comparable to the Eli Lilly-made drug substance that was evaluated in clinical trials. A larger study testing the prospective type 1 diabetes therapy teplizumab is ongoing and could provide the information the agency needs.

Medical device maker Dexcom is partnering with Livongo such that users of Livongo that have diabetes and use Dexcom’s continuous glucose monitoring system can sync their data on the Livongo platform.

Scores of users took to Facebook to express their dismay, frustration and anger at Dexcom when the CGM device company failed to properly keep them updated after an IT outage prevented type 1 diabetes patients from sharing data.

The Boston-based company said it would acquire Semma Therapeutics, which is developing a stem cell-derived therapy and device for the disease. Preclinical data were announced in July, and clinical trials are planned for 2020.

Medtronic announced data at the annual meeting of the American Diabetes Association on Monday that shows that people using its AI-powered Sugar.IQ diabetes assistant have better control of their blood glucose levels.

At the annual meeting of the American Diabetes Association meeting last week, a diabetes epidemiologist compares and contrasts competing CGMs both based on features and accuracy.

On the day that an FDA official exhorts industry to develop interoperable diabetes devices, Medtronic announces that it is teaming up with a nonprofit group to do just that.

Insulin prices have shot up nearly 600 percent, according to a congressional study, leading to potentially deadly rationing by many patients.

During a November 6 breakout session at MedCity ENGAGE, panelists shared that patients should be their own advocates, be part of their care team and stay informed.

The company, whose technology pairs with the Apple Watch and detects hand gestures, has a new feature that includes a reminder for mealtime insulin administration.

The California startup is attempting to create a closed-loop and integrated diabetes platform that attracted Abbott, whic has been a partner since July to invest.

Months ahead of schedule, FDA clears the use of DexCom’s latest continuous glucose monitoring system for patients two and up, freeing them from routine fingerstick calibration.

After a Type 1 patient penned a post on why she didn’t think Medtronic’s 670G hailed as the first artificial pancreas was all that, another patient who uses the device writes it’s exactly that and then some.

As a type 1 diabetes patient, I have decided to stay on an open-source insulin delivery solution instead of switching to a hybrid closed-loop insulin delivery system from Medtronic whose FDA approval was widely hailed.

A sooner-than-expected availability of a rival’s continuous glucose monitoring system to Medicare patients sends Dexcom’s stocks lower, but an analyst believes this will be temporary.

IBM and the Juvenile Diabetes Research Fund are teaming up to pinpoint the factors that lead to the onset of type 1 diabetes in children.

The development of type 1 diabetes starts years before symptoms appear, which raises the possibility of early intervention, prevention, or possibly even reversal of the disease. Such efforts were discussed on Monday at the American Diabetes Association’s Scientific Sessions.

The AHCA is back on the table, but not everyone is on board. Organizations like JDRF and even some House Republicans dissent, saying it increases burdens on those with pre-existing conditions.

Medicare announced that therapeutic continuous glucose monitors that help to make treatment decisions will be considered durable medical equipment and covered, a move hailed by many.